A phase II trial in patients with grade 3–4 neutropenia is currently underway to investigate the efficacy of secondary prophylaxis with G-CSF in the maintenance of FTD/TPI dose intensity and its effect on FTD/TPI treatment efficacy (https://clinicaltrials.gov/ct2/show/NCT04166604). Here, CSF3 is linked to frontotemporal dementia.